Jun. 4 at 12:03 PM
In its Q1 report,
$KRYS stated:
"As of April, the Company has secured over 540 reimbursement approvals for VYJUVEK in the U.S. and continues to maintain strong access nationwide including positive access determinations for 97% of lives covered under commercial and Medicaid plans."
In VYJUVEK's pivotal trial, 31 patients were enrolled - 30 with RDEB and only 1 with DDEB. Given that DDEB is significantly less severe, it’s reasonable to assume that the vast majority of reimbursements, say 500, were for RDEB patients. One can use this data to estimate the potential revenues of
$ABEO in the next two years, excluding royalties and global expansion.
